Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II proof concept study of RLM023 for Acne-vulgaris.

Trial Profile

Phase II proof concept study of RLM023 for Acne-vulgaris.

Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Hypochlorous acid (Primary)
  • Indications Acne vulgaris
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 15 Mar 2018 New trial record
    • 12 Mar 2018 According to a Realm Therapeutics media release, company intends to file an Investigational New Drug (IND) application in early Q4 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top